ENABLING FAIR ACCESS TO PHARMACOKINETIC AND PHARMACODYNAMIC RESULTS Characterization of absorption, distribution, metabolism, and excretion (ADME) drug parameters inform safety testing and future clinical studies. To augment their current capabilities in a time- and capital-efficient way, pharmaceutical and biotechnology firms often outsource compound synthesis and ADME/DMPK assays to Contract Research Organizations (CROs). Aside from cost savings, the challenges of manually transcribing unformatted or Excel-bound CRO reports dramatically slows the drug discovery and development process. Data availability and quality consumes scientists’ cycles, especially when biopharma sponsors work with multiple CROs. Note: most CROs maintain proprietary data formats for standard assays, and

Join for free to read